Advances in Stimuli-Responsive Nanosystems for Cancer Therapy

The book is a compilation of the latest developments in the technology and applications of stimuli-responsive nanosystems for cancer therapy. The book begins with an overview of recent advances in various stimuli, including endogenous triggers related to tumor microenvironments such as pH, temperature, enzymes and exogenous stimuli such as light, temperature, ultrasound and magnetic field, which could significantly augment anticancer therapy. A gamut of nanosystems investigated for cancer therapy, some major systems being liposomes, polymer nanoparticles, lipid nanoparticles, inorganic nanoparticles, hybrid nanoparticles and a range of other nanosystems which are stimuli responsive are covered in detail in the subsequent chapters. The chapters comprehensively cover the various nanosystems from development to evaluation to their application.  This book is a valuable resource for scientists, professors, researchers, as well as medical and industry professionals working in the area of cancer and targeted drug delivery.  It is also proposed as a textbook for master’s students opting for a course in targeted drug delivery

Padma V. Devarajan is Advisor and Chair Professor at the SIES School of Pharmaceutical Sciences with over three decades of experience as an academician and researcher. She was formerly Dean and Professor in Pharmacy and Member-Board of Governors, at the Institute of Chemical Technology, Mumbai, India. Her research focuses on the design and development of innovative targeted nanomedicine for cancer and infectious diseases, non-invasive bio-enhanced delivery of peptides, proteins, nucleic acids and interventions for veterinary health care. Her research addresses critical aspects such as scale-up, commercialization and affordability to ensure societal outreach. She has published extensively in peer-reviewed journals and is a reviewer for many journals. She has several patents and authored books. She is a recipient of several national and international research and innovation awards, including the Women in Science award of the Controlled Release Society Inc., USA.

Dr. Sathish Dyawanapelly is an Assistant Professor at the Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India. He has a Ph.D. in pharmaceutics from the Institute of Chemical Technology, Mumbai, and a master’s degree in pharmacy from the National Institute of Pharmaceutical Education and Research, Raebareli. His research area focuses on the design and development of drug delivery systems (polymer, lipid, and metal nanoparticles), biomaterials, nanomedicines, and pharmaceutical formulation technology. He has authored or co-authored numerous book chapters and published over 35 publications in peer-reviewed international journals and 3 book chapters. He developed and transferred 3 different technologies to industries. He is an Editorial member for Scientific Reports (Nature), PLOS ONE, Frontiers in Drug Delivery, Discover Pharmaceutical Sciences (Springer), and Current Indian Science (Bentham Science) and serves as a reviewer of peer-reviewed international journals. He is a member of many international scientific societies and organizations.

Vijayabhaskarreddy Junnuthula is a grant-funded researcher at the University of Helsinki, Finland. His research prominently revolves around the development of nanomedicine, spanning various domains within pharmaceutical sciences, most notably pharmaceutics, pharmacokinetics, and local drug delivery for diverse therapeutic applications. He has been supported by the Finnish Cultural Foundation and was a recipient of the Marie Curie Fellowship from the European Commission under the Horizon 2020 program. He was awarded the Solvay Chair Prize at the French Society of Nanomedicine conference in Bordeaux, France. He published several high-impact journals as an author. He is a peer reviewer for several pharmaceutical science journals, such as the International Journal of Pharmaceutics, Journal of Drug Delivery Science and Technology, BMC Pharmacology, Signal Transduction, and Targeted Therapy.